165 related articles for article (PubMed ID: 18780067)
1. Acute felon as a complication of systemic paclitaxel therapy: case report and review of the literature.
Hijjawi JB; Dennison DG
Hand (N Y); 2007 Sep; 2(3):101-3. PubMed ID: 18780067
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail.
Paul LJ; Cohen PR
J Drugs Dermatol; 2012 Feb; 11(2):262-8. PubMed ID: 22270214
[TBL] [Abstract][Full Text] [Related]
3. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel).
Ghetti E; Piraccini BM; Tosti A
J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):459-60. PubMed ID: 12834462
[TBL] [Abstract][Full Text] [Related]
4. Management and Outcome of Taxane-Induced Nail Side Effects: Experience of 79 Patients from a Single Centre.
Alessandrini A; Starace M; Cerè G; Brandi N; Piraccini BM
Skin Appendage Disord; 2019 Aug; 5(5):276-282. PubMed ID: 31559250
[TBL] [Abstract][Full Text] [Related]
5. [Exudative onycholysis and acute bacterial paronychia related to BIBF-1120 and paclitaxel: response to topical therapy].
Freites-Martínez A; Martinez-Sánchez D; de Pablo NP; Calderón-Komaromy A; Córdoba S; Burbujo J
Invest Clin; 2014 Mar; 55(1):55-60. PubMed ID: 24758102
[TBL] [Abstract][Full Text] [Related]
6. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.
Hussain S; Anderson DN; Salvatti ME; Adamson B; McManus M; Braverman AS
Cancer; 2000 May; 88(10):2367-71. PubMed ID: 10820360
[TBL] [Abstract][Full Text] [Related]
7. Acute felon and paronychia: Antibiotics not necessary after surgical treatment. Prospective study of 46 patients.
Pierrart J; Delgrande D; Mamane W; Tordjman D; Masmejean EH
Hand Surg Rehabil; 2016 Feb; 35(1):40-3. PubMed ID: 27117023
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel: a review of adverse toxicities and novel delivery strategies.
Marupudi NI; Han JE; Li KW; Renard VM; Tyler BM; Brem H
Expert Opin Drug Saf; 2007 Sep; 6(5):609-21. PubMed ID: 17877447
[TBL] [Abstract][Full Text] [Related]
9. Future directions of paclitaxel-based therapy of breast cancer.
Gianni L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-91-S17-96. PubMed ID: 9374103
[TBL] [Abstract][Full Text] [Related]
10. [Paclitaxel (Taxol)].
Hájek R
Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-induced nail dystrophy.
Nicolopoulos J; Howard A
Australas J Dermatol; 2002 Nov; 43(4):293-6. PubMed ID: 12423438
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
14. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
Eniu A; Palmieri FM; Perez EA
Oncologist; 2005 Oct; 10(9):665-85. PubMed ID: 16249346
[TBL] [Abstract][Full Text] [Related]
15. Onycholysis associated with weekly administration of paclitaxel.
Flory SM; Solimando DA; Webster GF; Dunton CJ; Neufeld JM; Haffey MB
Ann Pharmacother; 1999 May; 33(5):584-6. PubMed ID: 10369623
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration.
Roh MR; Cho JY; Lew W
Yonsei Med J; 2007 Feb; 48(1):124-6. PubMed ID: 17326255
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-Induced Periarticular Thenar Erythema with Onycholysis Syndrome.
Kaur J; Gaurav V; Tyagi M
Skin Appendage Disord; 2024 Feb; 10(1):74-77. PubMed ID: 38313568
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Nail Lacquer on Taxane-Induced Nail Changes in Women With Breast Cancer.
Alshari O; Aleshawi A; Al Sharie AH; Msameh A; Al-Omari I; Msameh R; Almegdadi A; Albals D
Breast Cancer (Auckl); 2020; 14():1178223420929702. PubMed ID: 32595274
[TBL] [Abstract][Full Text] [Related]
20. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
